Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
about
Inferring microRNA regulation of mRNA with partially ordered samples of paired expression data and exogenous prediction algorithms.Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.
P2860
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Thalidomide in total therapy 2 ...... ocorticoid receptor gene NR3C1
@en
type
label
Thalidomide in total therapy 2 ...... ocorticoid receptor gene NR3C1
@en
prefLabel
Thalidomide in total therapy 2 ...... ocorticoid receptor gene NR3C1
@en
P2093
P2860
P50
P1476
Thalidomide in total therapy 2 ...... ocorticoid receptor gene NR3C1
@en
P2093
Bijay Nair
Christoph J Heuck
Clyde Bailey
Emily Hansen
Jackie Szymonifka
John Crowley
John D Shaughnessy
Joshua Epstein
Nathan Petty
Saad Z Usmani
P2860
P304
P356
10.1158/1078-0432.CCR-12-0019
P407
P577
2012-08-01T00:00:00Z